


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A non-naturally occurring, biologically active compound having the formula F-A



where

~~R is an organic moiety comprising at least one consists of at least one carbohydrate moiety and/or at least one Pet (pentaerythritol) unit, and optionally, one or more spacers, and optionally a trivalent or tetravalent linker;~~

Ch is chalcogen;

R₂ is hydrogen, or an organic moiety consisting of at least one primarily alkyl moiety and, optionally, one or more spacers;

R₃ is -CH₂-R₃' or -C(=Ch)-R₃', where R₃' is an organic moiety ~~comprising a steroid moiety, an alkaloid moiety, a terpenoid moiety,~~ consisting of a polyunsaturated moiety or a primarily alkyl moiety, and, optionally, one or more spacers, and optionally a trivalent or tetravalent linker.

A is CH₂OH or is an organic moiety consisting of at least one primarily alkyl moiety and, optionally, one or more spacers; and

at least one of the following conditions applies:

~~(1) said compound comprises at least one steroid moiety, and/or at least one alkaloid moiety;~~

~~(2) (1) R3' comprises consists of at least one polyunsaturated moiety and optionally one or more spacers;~~

~~(3) (2) R3' is of the form -(trivalent or tetravalent linker)(-spacer-T^a)_a(-T^b)_b, where linker is an aliphatic moiety with not more than 12 non-hydrogen atoms, and consisting of one or more alkyl moieties and/or one or more spacers, a and b are integers each in the range of 0-3, and a+b is in the range of 1-3 2-3, except that if a=0, b is at least 2, and T^a and T^b are, independently, organic moieties consisting of at least one primarily alkyl moiety and, optionally, one or more spacers, which may differ for each of the a instances of T^a and each of the b instances of T^b; or~~

(3) A is -CH₂OH;

~~(4) A is -CH(-spacer-R4)-R1 where~~

~~—— (A) R1 is hydrogen, and R4 is hydrogen or an organic moiety consisting of at least one primarily alkyl moiety and, optionally, one or more spacers;~~

~~—— (B) R1 is an organic moiety consisting of at least one primarily alkyl moiety and, optionally, one or more spacers;~~

~~and R4 is an organic moiety consisting of at least one primarily alkyl moiety and, optionally, one or more spacers,~~

~~— (C) R1 is -(spacer cluster)-(organic moiety) and R4 is hydrogen, -(organic moiety), or -(spacer)-(organic moiety), where each organic moiety is one consisting of at least one primarily alkyl moiety and, optionally, one or more spacers, and~~

~~(5) A is -(spacer cluster)-R1, where R1 is hydrogen or an organic moiety consisting of at least one primarily alkyl moiety and, optionally, one or more spacers~~

each trivalent or tetravalent linker being, independently, an aliphatic moiety with not more than 12 non-hydrogen atoms, and consisting of one or more alkyl moieties and/or one or more spacers;

each spacer being selected independently from the group consisting of -NR*- , -C(=O)- , -C(=S)- , -O- and -S- , wherein R* is H or alkanyl of 1-4 carbons.

2. (Original) The compound of claim 1 where each of the organic moieties consists of not more than 120 atoms other than hydrogen atoms.

3. (Original) The compound of claim 1 where each chalcogen is oxygen.

4. (Original) The compound of claim 1 in which R2 is hydrogen.

USSN - 10/529,393

5-6 (Cancelled).

7. (Original) The compound of claim 1 where condition (1) applies.

8-9 (Cancelled).

10. (Original) The compound of claim 1 where condition (2) applies.

11. (Currently Amended) The compound of claim ~~10~~ 7 where the polyunsaturated moiety comprises at least one methylene-interrupted pair of alkenic double bonds (-C=C-C-C=C-).

12. (Original) The compound of claim 11 where the carbon skeleton of R₃ is the same as the carbon skeleton of the fatty acyl moiety of arachidonic acid.

13 (cancelled).

14. (Currently amended) The compound of claim ~~13~~ 10 in which each T^a and T^b is an independently chosen primarily alkyl moiety.

15-16 (Cancelled).

17. (Original) The compound of claim 14 in which the linker is trivalent.

18. (Original) The compound of claim 17 in which R₃' is of the form -CH₂-CH(-R₃'Rem₂)-R₃'Rem₁, and R₃'Rem₁ and R₃'Rem₂

are independently chosen organic moieties consisting of at least one primarily alkyl moiety and, optionally, one or more spacers.

19. (Currently Amended) The compound of claim 17 in which R3' is of a form selected from the group consisting of


- CH₂-CH(-R_{3b})-(spacerA1)-(spacerA2)-R₃"
- CH₂-CH(-R_{3b})-(spacerA)-R₃"
- CH₂-CH(-(spacerB)-R_{3b})-(spacerA1)-(spacerA2)-R₃"
- CH₂-CH(-(spacerB)-R_{3b})-(spacerA)-R₃"
- CH(-R_{3b})-(spacerA1)-(spacerA2)-R₃"
- CH(-R_{3b})-(spacerA)-R₃"
- CH(-(spacerB)-R_{3b})-(spacerA1)-(spacerA2)-R₃"
- CH(-(spacerB)-R_{3b})-(spacerA)-R₃"

where each of spacerA, spacerA1, spacerA2 and spacerB is an independently chosen spacer, and R₃" and R_{3b} are primarily alkyl moieties.


20. (Currently Amended) The compound of claim ~~18~~ 19 in which SpacerA1 is -NH- or -O-, Spacer A2 is -C(=O)-, SpacerA is -O-, and SpacerB is -O-.

21-49 (Cancelled).

50. (Currently Amended) ~~The A compound of claim 49, further~~ defined by the following structure:




wherein R is chosen from structure I or II,




wherein R^3 is a substitution group selected from the group consisting of

- (i) $-\text{CO}(\text{CF}_2)_m\text{CF}_3$
- (ii) $-\text{COCF}_2(\text{CH}_2)_m\text{CH}_3$
- (iii) $-\text{CO}(\text{CH}_2)_x(\text{CH}=\text{CHCH}_2)_2(\text{CH}=\text{CHCH}_2)_n(\text{CH}_2)_m\text{CH}_3$


(iv)




(v)



(vi)




(vii)



and


(viii)



wherein M is CH₂ or CO; k and m are independent integers with values from 0 to 30, and n and p are independent integers with values from 0 to 10, and


R⁴ is H or OH, and R⁵ is H; or R⁴ and R⁵ form a double bond.

51. (Original) The compound of claim 50, having the structure



52-62 (Cancelled).

63. (Currently amended) A non-naturally occurring, biologically active ~~The compound of claim 62, further~~ defined by the following structure:



38


wherein R3 is as previously defined a substitution group selected from the group consisting of

(i) $-\text{CO}(\text{CF}_2)_m\text{CF}_3$


(ii) $-\text{COCF}_2(\text{CH}_2)_m\text{CH}_3$

(iii) $-\text{CO}(\text{CH}_2)_r(\text{CH}=\text{CHCH}_2)_2(\text{CH}=\text{CHCH}_2)_n(\text{CH}_2)_m\text{CH}_3$


(iv)



(v)




(vi)




18

(vii)




(viii)




(ix) $-CO(CH_2)_mCH(OH)(CH_2)_kCH_3$

wherein M is CH_2 or CO ; k and m are independent integers with values from 0 to 30, and n and p are independent integers with values from 0 to 10.

64. (Currently Amended) The compound of claim 63 where the R_3 therein has ~~the~~ a structure selected from the group consisting of



65. (Original) The compound of claim 64 which has the structure



66-91 (Cancelled).

92. (Currently Amended) The compound of claim \pm 160 where the carbohydrate moiety is a monosaccharide.

93. (Currently Amended) The compound of claim \pm 160 where said carbohydrate moiety comprises at least one sugar unit which is hexosyl, pentosyl, or nonosyl.

94. (Original) The compound of claim 93 in which each sugar unit is hexosyl, pentosyl or nonosyl.

95. (Currently Amended) The compound of claim 94 in which each sugar unit is (a) galactose, glucose, mannose or fucose, (b) a deoxy or N-acetyl derivative of (a), ~~of~~ or (c) a sialic acid.

96. (Currently Amended) The compound of claim 1 where the inner sugar unit is galactose.

97. (Original) The compound of claim 96 where the inner sugar unit is alpha-galactose.

98. (Original) A compound selected from the group consisting of compounds 1-5 in Fig. 11, 8-13 in Fig. 12, and 033 in Fig. 31.

99. (Currently amended) A pharmaceutically acceptable composition comprising at least one compound according to claim ~~±~~205.

100. (Original) The composition of claim 99, where said compound has immunodulatory activity, and further comprising at least one immunomodulatory agent which is not one of said compounds.

101. (Original) The composition of claim 100, where at least one such immunomodulatory agent is an immunogen.

102. (Previously presented) The composition of claim 100,

where at least one such immunomodulatory agent is an adjuvant.

103. (Original) The composition of claim 102, where said adjuvant is selected from the group consisting of lipid A, lipid A analogues, CpG-containing oligonucleotides, muramyl dipeptides, sitosterols, alum, and QS-21.

104. (Original) The composition of claim 99, further comprising at least one antiviral, antibacterial, antiparasitic or antitumor agent other than said compound.

105. (Currently Amended) The composition of claim 99, in liposomal form.

106. (Cancelled)

107. (Currently amended) A method of protecting a mammalian subject against a virus, microbial infection, parasite or cancer which comprises administering to the subject a pharmaceutically effective amount of a compound according to claim ~~±~~205 which has pharmaceutical activity against such virus, microbial infection, parasite, or cancer.

108. (Original) The method of claim 107 wherein protection is against a virus.

109. (Original) The method of claim 108 wherein said virus is HIV-1.

110. (Original) The method of claim 107 wherein protection

is against a cancer.

111. (Original) The method of claim 110 which further comprises administration of an immunogen comprising a tumor-associated epitope.

112. (Original) The method of claim 111 where said immunogen comprises a MUC1 epitope.

113. (Original) The method of claim 111 where said immunogen comprises a Tn, TF, sialyl Tn, sialylTF, F1- α , Globo H, Fucosyl GM1, or GalNAc GM1 epitope.

114. (Original) The method of claim 110 wherein said cancer is a melanoma.

115. (Original) The method of claim 107 wherein protection is against a microbial infection.

116. (Original) The method of claim 115 wherein the microbial infection is a malaria infection.

117. (Original) The method of claim 115 wherein the microbial infection is a tuberculosis infection.

118. (Currently amended) A method of protecting a subject against an immune ~~disease~~ disease or an inflammation which comprises administering an immunoinhibitory amount of a compound according to claim ~~±~~205.

119. (Original) The method of claim 118 where said

protection is against an autoimmune disease.

120. (Original) The method of claim 119 wherein said autoimmune disease is diabetes.

121. (Original) The method of claim 119 wherein said autoimmune disease is asthma, eczema, multiple sclerosis or rheumatoid arthritis.

122. (Original) The method of claim 118 where said protection is against inflammation.

123. (Previously presented) The method of claim 107 further comprising administering a pharmaceutically effective amount of at least one immunomodulatory agent which is not one of said compounds.

124. (Original) The method of claim 123, where at least one such immunomodulatory agent is an immunogen.

125. (Original) The method of claim 123, where at least one such immunomodulatory agent is an adjuvant.

126. (Original) The method of claim 125, where said adjuvant is selected from the group consisting of lipid A, lipid A analogues, CpG-containing oligonucleotides, muramyl dipeptides, sitosterols, alum, and QS-21.

127. (Previously presented) The composition of claim 107, further comprising a pharmaceutically effective amount of at least one antiviral, antibacterial, antiparasitic or

antitumor agent other than said compound.

128. (Currently Amended) The compound of claim ~~±205~~ which has immunostimulatory activity.

129. (Original) A method of stimulating the immune system of a mammalian subject which comprises administering to said subject an immunostimulatory amount of the compound of claim 128.

130. (Original) The method of claim 129 which further comprises administering to the subject an immunologically effective amount of an immunogen, the immune response to said immunogen being enhanced by said compound.

131. (Original) The method of claim 130 in which the immunogen is a disease-associated immunogen and the subject suffers from that disease.

132. (Original) The method of claim 131 in which the immunogen is a tumor-associated immunogen.

133. (Previously presented) The method of claim 130 in which the immunogen comprises a carbohydrate epitope.

134. (Original) The method of claim 133 in which the immunogen comprises a Tn, TF or sialyl-Tn epitope.

135. (Previously presented) The method of claim 130 in which the immunogen comprises a peptide epitope.

136. (Original) The method of claim 135 in which the immunogen comprises a MUC1 epitope.

137. (Previously presented) The method of claim 129 in which the compound is delivered by means of a liposomal formulation.

138. (Previously presented) The method of claim 129 in which the immunogen comprises a strongly lipophilic group.

139. (Previously presented) The method of claim 129 in which the immunogen is delivered by means of a liposomal formulation.

140-142 (Cancelled).

143. (Currently Amended) The compound of claim 1 which has a molecular weight of less than 10,000 daltons.

144. (Previously Presented) The compound of claim 143 which has a molecular weight less than 5,000 daltons.

145. (Currently Amended) The compound of claim 143 which has a molecular weight , less than 2,500 daltons.

146. (Previously Presented) The compound of claim 143 which has a molecular weight less than 1,000 daltons.

147. (Cancelled)

148. (Previously Presented) The compound of claim 1 in

which R is an organic moiety comprising at least one carbohydrate moiety and Ch is oxygen.

149. (Previously Presented) The compound of claim 148 in which the carbohydrate moiety is galactose.

150. (Previously Presented) The compound of claim 1 in which A comprises at least one carbon-carbon double bond.

151. (Previously Presented) The compound of claim 1 in which A comprises at least one hydroxyl group.

152. (Previously Presented) The compound of claim 1 in which A is $-C(OH)-C=C-(CH_2)_{12}-CH_3$.

153. (Currently Amended) The compound of claim 1 in which Ch is oxygen and R2 is hydrogen.


154. (Currently amended) The compound of claim 1 in which R3 is $-C(=O)-R3'$, and R3' is ~~an organic moiety comprising~~ a polyunsaturated moiety.

155. (Previously Presented) The compound of claim 154 in which R3' comprises at least two methylene-interrupted double bonds.

156. (Previously Presented) The compound of claim 155 in which R3' is an (n-6) methylene-interrupted polyunsaturated moiety.

157. (Previously Presented) The compound of claim 156 in

which R3' is



158. (Currently Amended) The compound of claim 1 in which

R is galactose,

Ch is oxygen,

R2 is hydrogen,

R3 is $-\text{C}(=\text{O})-\text{R3}'$, where

R3' is $-(\text{CH}_2)_3-(\text{CH}=\text{CH}-\text{CH}_2)_4-(\text{CH}_2)_3-\text{CH}_3$, and

A is $-\text{CH}(\text{OH})-\text{CH}=\text{CH}-(\text{CH}_2)_{12}-\text{CH}_3$.

159 (New). The compound of claim 1, wherein R comprises at least one carbohydrate moiety.

160 (New). The compound of claim 159 wherein R is a carbohydrate moiety.

161 (New). The compound of claim 160 wherein R is a carbohydrate moiety consisting of 1-20 sugar units.

162 (New). The compound of claim 160 wherein R is a carbohydrate moiety consisting of 1-6 sugar units.

163 (New). The compound of claim 160 wherein R is the carbohydrate moiety of a naturally occurring glycosphingolipid or glycosylceramide, or the carbohydrate epitope of a naturally occurring antigen.

164 (New). The compound of claim 160 wherein R is the carbohydrate moiety of a naturally occurring

glycosylceramide.

165 (New). The compound of claim 95 wherein the inner sugar unit is galactose or glucose.

166 (New). The compound of claim 165 wherein the carbohydrate moiety consists of 1-6 sugar units.

167 (New). The compound of claim 165 wherein the carbohydrate moiety consists of 1-5 sugar units.

168 (New). The compound of claim 167 wherein R is the carbohydrate moiety of a naturally occurring glycosylceramide.

169 (New). The compound of claim 167 wherein Ch is oxygen and R2 is hydrogen.

170 (New). The compound of claim 168 wherein Ch is oxygen and R2 is hydrogen.

171 (New). The compound of claim 1 wherein R is galactose, Ch is oxygen, and R2 is hydrogen.

172 (New). The compound of claim 169 wherein R3 is -C(=O)-R3', and R3' is a polyunsaturated moiety that is a hydrocarbon.





173 (New). The compound of claim 172 wherein R3 is characterized by 10-40 carbon atoms and R3' is characterized by 2-10 olefinic bonds.

USSN - 10/529,393



174 (New). The compound of claim 173 wherein all olefinic double bonds of R3' belong to methylene-interrupted pairs of olefinic double bonds.

175 (New). The compound of claim 174 wherein R3' comprises -CH=CH-CH₂-CH-CH)₄-.

176 (New). The compound of claim 169 wherein R3 is selected from the group consisting of




and



wherein k= 0 to 30, 0 to 30, n = 0 to 10, and M is CH₂ or CO.

177 (New). The compound of claim 169 wherein R3 is



wherein k = 0 to 30, m = 0 to 30, and n = 0 to 10.

178 (New). The compound of claim 177, wherein k=3, n=2, and m=4.


179 (New). The compound of claim 169 wherein R3' is -C(=O)-CH₂-CH(-O-M-(CH₂)_m-(CH=CH)_n-(CH=CHCH₂)_p-CH₃)-(CH₂)_k-CH₃, wherein M is CH₂ or CO; k and m are independent integers with values from 0 to 30, and n and p are independent integers with

values from 0 to 10.

180 (New). The compound of claim 169 wherein R3 is -C(=O)-R3' and R3' is alkanyl or polyunsaturated alkenyl or -CH(-O-alkanyl)-alkanyl.

181 (New). The compound of claim 180 wherein said alkanyl and alkenyl of R3' individually do not exceed 25 carbon atoms.

182 (New). The compound of claim 169 where the R3 therein has the structure



183 (New). The compound of claim 171 wherein R3 is -C(=O)-R3', and R3' is a polyunsaturated moiety that is a hydrocarbon.

184 (New). The compound of claim 183 wherein R3 is characterized by 10-40 carbon atoms and R3' is characterized by 2-10 olefinic bonds.

185 (New). The compound of claim 184 wherein all olefinic double bonds of R3' belong to methylene-interrupted

pairs of olefinic double bonds.

186 (New). The compound of claim 185 wherein R3' comprises $-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}(\text{CH}_3)_4-$.

187 (New). The compound of claim 169 wherein A is $-\text{CH}_2\text{OH}$, $-\text{CHOH}-\text{alkanyl}$, $-\text{CHOH}-\text{alkenyl}$, $-\text{CHOH}-\text{hydroxyalkanyl}$ or $-\text{CHOH}-\text{hydroxyalkenyl}$.

188 (New). The compound of claim 187 wherein A is $-\text{CH}_2\text{OH}$.

189 (New). The compound of claim 187 wherein A is $-\text{CHOH}-\text{alkanyl}$, $-\text{CHOH}-\text{alkenyl}$, $-\text{CHOH}-\text{hydroxyalkanyl}$ or $-\text{CHOH}-\text{hydroxyalkenyl}$.

190 (New). The compound of claim 189 wherein said alkanyl, alkenyl, hydroxyalkanyl or hydroxyalkenyl of A does not exceed 25 carbon atoms.

190 (New). The compound of claim 187 wherein A is $-\text{CHOH}-\text{alkenyl}$ or $-\text{CHOH}-\text{hydroxyalkenyl}$.

191 (New). The compound of claim 190 wherein A is characterized by a single olefinic double bond.

192 (New). The compound of claim 191 wherein A is $-\text{CHOH}-\text{CH}=\text{CH}-\text{alkanyl}$.

193 (New). The compound of claim 192 wherein A is $-\text{CHOH}-\text{CH}=\text{CH}(\text{CH}_2)_i\text{CH}_3$, wherein i is 6 to 20.

194 (New). The compound of claim 193 wherein i is 12.

195 (New). The compound of claim 169 wherein A is $-\text{CHOH}-\text{R1}$ and R1 is a substitution group selected from the group consisting of

- $-\text{CH}_2(\text{CH}_2)_i\text{CH}_3$,
- $-\text{CH}=\text{CH}(\text{CH}_2)_i\text{CH}_3$,
- $-\text{CH}(\text{OH})(\text{CH}_2)_i\text{CH}_3$,
- $-\text{CH}_2(\text{CH}_2)_i\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_3$, and
- $-\text{CH}(\text{OH})(\text{CH}_2)_i\text{CH}(\text{CH}_3)_2$,

wherein i is an integer with values from 6 to 20.

196 (New). The compound of claim 189 wherein said alkanyl, alkenyl, hydroxyalkanyl or hydroxyalkenyl of A is characterized by 8 to 25 carbon atoms.

197 (New). The compound of claim 196 wherein said hydroxyalkanyl or hydroxyalkenyl is characterized by a single hydroxyl group.

198 (New). The compound of claim 171 wherein A is -CH₂OH, -CHOH-alkanyl, -CHOH-alkenyl, -CHOH-hydroxyalkanyl or -CHOH-hydroxyalkenyl.

199 (New). The compound of claim 198 wherein A is -CH₂OH.

200 (New). The compound of claim 199 wherein A is -CHOH-alkanyl, -CHOH-alkenyl, -CHOH-hydroxyalkanyl or -CHOH-hydroxyalkenyl.

201 (New). The compound of claim 189 wherein R₃ is -C(=O)-R₃', and R₃' is a polyunsaturated moiety that is a hydrocarbon.

202 (New). The compound of claim 201 wherein R₃ is characterized by 10-40 carbon atoms and R₃' is characterized by 2-10 olefinic bonds.

203 (New). The compound of claim 202 wherein all olefinic double bonds of R₃' belong to methylene-interrupted pairs of olefinic double bonds.

204 (New). The compound of claim 203 wherein R₃' comprises -CH=CH-CH₂-CH-CH)₄-.

205 (New). The compound of claim 189 wherein R₃ is -C(=O)-R₃', and R₃' is a polyunsaturated moiety that is a hydrocarbon.

206 (New). The compound of claim 205 wherein R₃ is characterized by 10-40 carbon atoms and R₃' is

characterized by 2-10 olefinic bonds.

207 (New). The compound of claim 206 wherein all olefinic double bonds of R3' belong to methylene-interrupted pairs of olefinic double bonds.

208 (New). The compound of claim 207 wherein R3' comprises $-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}(\text{CH}_3)-$.

209 (New). The compound of claim 200 wherein said alkanyl, alkenyl, hydroxyalkanyl or hydroxyalkenyl of A is characterized by 8 to 25 carbon atoms.

210 (New). The compound of claim 209 wherein said hydroxyalkanyl or hydroxyalkenyl is characterized by a single hydroxyl group.

211 (New). The compound of claim 209 wherein A is $-\text{CHOH}-\text{alkenyl}$.

212 (New). The compound of claim 211 wherein A is characterized by a single olefinic double bond.

213 (New). The compound of claim 212 wherein A is $-\text{CHOH}-\text{CH}=\text{CH}-\text{alkanyl}$.

214 (New). The compound of claim 211 wherein R3 is $-\text{C}(=\text{O})-\text{R3}'$, and R3' is a polyunsaturated moiety that is a hydrocarbon.

215 (New). The compound of claim 214 wherein R3 is characterized by 10-40 carbon atoms and R3' is characterized by 2-10 olefinic bonds.

216 (New). The compound of claim 215 wherein all olefinic double bonds of R3' belong to methylene-interrupted pairs of olefinic double bonds.

217 (New). The compound of claim 216 wherein R3' comprises $-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}(\text{CH}_3)-$.

218 (New). The compound of claim 1, wherein all spacers are $-\text{O}-$ or $-\text{C}(=\text{O})-$.